Maximus vs BreezeMeds: Price, Delivery, and Options Compared

Quick verdict: Maximus vs BreezeMeds

Maximus is the lower-cost, telemedicine-first option offering compounded semaglutide starting at $132.99/month through trusted U.S. pharmacies. BreezeMeds starts higher, with injectable semaglutide listed from $199/month and additional oral and tirzepatide options; confirm product, price, and eligibility before enrolling. This article compares Maximus vs BreezeMeds on price, medication types, delivery and program model, and regulatory notes.

Visit Maximus pricing and program details

Price and monthly cost comparison

Direct-cost is the clearest difference between Maximus and BreezeMeds. Maximus advertises compounded semaglutide starting at $132.99/month and describes a low flat rate and transparent pricing. BreezeMeds displays a range: semaglutide injection from $199/month; tirzepatide injection from $299; and oral options from $399, plus a separate $169 figure that is not clearly tied to a specific product.

Medication types and availability

Maximus focuses on compounded semaglutide filled through U.S. pharmacies and notes compounded medication status. BreezeMeds lists injectable and oral semaglutide and tirzepatide options and indicates both injectable and oral forms are displayed. For BreezeMeds, medication-specific approval status and whether products are branded or compounded must be confirmed.

Delivery model, telemedicine, and personalization

Both providers use online intake or telemedicine but present different emphases. Maximus emphasizes convenient telemedicine access with prescriptions approved by licensed doctors and filled through trusted U.S. pharmacies, with no clinic visits required. BreezeMeds highlights online intake, a personalized treatment plan, and discreet home delivery, and notes that treatment is available only when a licensed clinician determines it is medically appropriate.

Regulatory and compounding notes

Both sources include regulatory qualifiers. Maximus states that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. BreezeMeds notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. These qualifiers mean you should confirm product status and clinician review when enrolling with either provider.

Distinctive differences at a glance

Program details, refunds, and state availability

Maximus specifies that if you are not approved for treatment, medication costs will be fully refunded and that the Weight Loss Protocol is available in all 50 states except Mississippi. BreezeMeds does not have captured FAQ detail in the source; the site prompts users to confirm costs, insurance, and state availability during intake.

Practical considerations when choosing

When weighing Maximus vs BreezeMeds, consider five practical points. First, cost sensitivity: Maximus lists a lower flat rate starting at $132.99/month. Second, product variety: BreezeMeds displays injectable and oral options and lists tirzepatide, which may matter if you want non-injectable formulations. Third, confirmation of product status: both sources require you to confirm whether a product is branded or compounded and clinician eligibility. Fourth, delivery preference: Maximus emphasizes U.S. pharmacies and expedited shipping; BreezeMeds highlights discreet shipping and a personalized plan. Fifth, state and approval limits: Maximus lists state availability with one exception; BreezeMeds advises confirming state service during intake.

See Maximus availability, pricing, and telemedicine process

Conclusion: Maximus vs BreezeMeds

Maximus vs BreezeMeds comes down to lower advertised monthly cost and a simple compounded semaglutide program versus a wider display of medication formats and higher starting prices. Maximus is the lower-cost, telemedicine-first choice starting at $132.99/month with compounded semaglutide filled through U.S. pharmacies. BreezeMeds lists semaglutide injections from $199/month and also displays oral and tirzepatide options; medication-specific approval status and product details should be confirmed before enrolling.

Choose one if…

Choose Maximus if you want a straightforward, lower flat rate telemedicine program for compounded semaglutide starting at $132.99/month with prescriptions filled through trusted U.S. pharmacies and availability in most states. Choose BreezeMeds if you want a provider that lists injectable and oral semaglutide or tirzepatide options and prefer to confirm personalized treatment, product type, pricing, and state availability during intake.